Short-term immunosuppression enhances long-term survival of bovine chromaffin cell xenografts in rat CNS.
Xenogeneic donors, a largely untapped resource, would solve many of the problems associated with the limited availability of human donor tissue for neural transplantation. Previous work in our laboratory has revealed that xenografts of isolated bovine chromaffin cells survive transplantation into the periaqueductal gray (PAG) of immunosuppressed adult rats. Electron microscopic analysis reveals that graft sites contain healthy chromaffin cells, but do not contain host immune cells typical of graft rejection. The aim of the current study was to assess the necessary conditions for long-term survival of bovine chromaffin cell xenografts in the central nervous system (CNS). In particular, the need for short-course vs. permanent immunosuppressive therapy with cyclosporine A (CsA) for the long-term survival of grafted bovine chromaffin cells was addressed. Grafts from animals receiving continuous CsA treatment for either 3, 6, or 12 wk contained large clumps of dopamine-beta-hydroxylase (DBH) positive cells in contrast to the few surviving cells observed in nonimmunosuppressed animals. In addition, grafts from animals that had CsA treatment terminated at 3 or 6 wk contained similarly large clumps of DBH-positive cells. Furthermore, short-term immunosuppression (3 wk) appeared to enhance the long-term survival of grafted cells, since clumps of DBH staining cells could still be positively identified in the host PAG at least 1 yr after transplantation. Complete rejection of graft tissue depends on several factors, such as blood-brain barrier integrity, the presence of major histocompatibility complex (MHC) antigens in either the host or graft, and the status of the host immune system.(ABSTRACT TRUNCATED AT 250 WORDS)
Ortega
J D
JD
Department of Anatomy and Cell Biology, University of Illinois at Chicago 60612.
Sagen
J
J
Pappas
G D
GD
D000313:Adrenal Medulla / Q000166:cytology / Q000637:transplantation*; D000818:Animals; D002417:Cattle; D002478:Cells, Cultured; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D004299:Dopamine beta-Hydroxylase / Q000032:analysis; D004744:Enkephalin, Methionine / Q000032:analysis; D006085:Graft Survival / Q000276:immunology*; D007150:Immunohistochemistry; D007165:Immunosuppression Therapy / Q000379:methods*; D008297:Male; D010487:Periaqueductal Gray; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology*; D016042:Transplantation, Heterotopic / Q000276:immunology*; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D053379:Chromogranin A; D002864:Chromogranins; D004744:Enkephalin, Methionine; D016572:Cyclosporine; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase